Wiley Partners with OpenEvidence to Accelerate Medical Research Integration at Point of Care

Event summary

  • Wiley (NYSE: WLY) and OpenEvidence have formed a strategic partnership to integrate Wiley’s peer-reviewed medical content into OpenEvidence’s AI platform.
  • The collaboration includes licensing the Cochrane Database of Systematic Reviews and over 400 Wiley journals and books across key medical specialties.
  • OpenEvidence, used by 40% of U.S. physicians, will now provide deeper access to trusted evidence at the point of care.
  • Wiley’s content spans cardiology, oncology, neurology, and other fields, reinforcing OpenEvidence’s evidence layer.

The big picture

This partnership addresses a critical bottleneck in medicine: the slow translation of research into clinical practice. By embedding Wiley’s authoritative content into OpenEvidence’s AI-driven platform, the collaboration aims to streamline evidence-based decision-making for physicians. The move reflects broader industry trends toward AI-powered knowledge integration in healthcare, where trusted data sources are key to adoption.

What we're watching

Content Expansion
Whether Wiley’s addition of Cochrane and other specialized content will further differentiate OpenEvidence in a competitive medical AI landscape.
Clinical Adoption
The pace at which physicians integrate this enhanced evidence layer into routine decision-making, reducing the 17-year research-to-practice gap.
Future Collaborations
How Wiley and OpenEvidence may extend their partnership beyond content licensing into global expansion or other healthcare use cases.

Related topics

Partnership